Want to see SRPT full AI Analyst Report?
Total Valuation
Sarepta Therapeutics has a market cap or net worth of $1.57B. The enterprise value is $2.15K.
Market Cap$1.57B
Enterprise Value$2.15K
Share Statistics
Sarepta Therapeutics has 105,576,225 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding105,576,225
Owned by Insiders6.16%
Owned by Institutions4.62%
Financial Efficiency
Sarepta Therapeutics’s return on equity (ROE) is -0.63 and return on invested capital (ROIC) is -29.03%.
Return on Equity (ROE)-0.63
Return on Assets (ROA)-0.21
Return on Invested Capital (ROIC)-29.03%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee2.63M
Profits Per Employee-854.38K
Employee Count835
Asset Turnover0.66
Inventory Turnover0.96
Valuation Ratios
The current PE Ratio of Sarepta Therapeutics is 24.0. Sarepta Therapeutics’s PEG ratio is 0.00777.
PE Ratio24.0
PS Ratio1.03
PB Ratio1.98
Price to Fair Value1.98
Price to FCF-7.33
Price to Operating Cash Flow-19.30
PEG Ratio0.00777
Income Statement
In the last 12 months, Sarepta Therapeutics had revenue of 2.20B and earned -713.41M in profits. Earnings per share was -7.13.
Revenue2.20B
Gross Profit1.32B
Operating Income-657.77M
Pretax Income-702.23M
Net Income-713.41M
EBITDA-647.97M
Earnings Per Share (EPS)-7.13
Cash Flow
In the last 12 months, operating cash flow was -91.67M and capital expenditures -39.79M, giving a free cash flow of -131.47M billion.
Operating Cash Flow-91.67M
Free Cash Flow-131.47M
Free Cash Flow per Share-1.25
Dividends & Yields
Sarepta Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.30
52-Week Price Change-6.47%
50-Day Moving Average16.89
200-Day Moving Average19.26
Relative Strength Index (RSI)51.20
Average Volume (3m)3.58M
Important Dates
Sarepta Therapeutics upcoming earnings date is Nov 4, 2026, After Close (Confirmed).
Last Earnings DateAug 5, 2026
Next Earnings DateNov 4, 2026
Ex-Dividend Date―
Financial Position
Sarepta Therapeutics as a current ratio of 2.32, with Debt / Equity ratio of 68.45%
Current Ratio2.32
Quick Ratio1.48
Debt to Market Cap0.37
Net Debt to EBITDA-0.37
Interest Coverage Ratio-67.60
Taxes
In the past 12 months, Sarepta Therapeutics has paid 11.19M in taxes.
Income Tax11.19M
Effective Tax Rate-0.02
Enterprise Valuation
Sarepta Therapeutics EV to EBITDA ratio is -3.85, with an EV/FCF ratio of -8.11.
EV to Sales1.13
EV to EBITDA-3.85
EV to Free Cash Flow-8.11
EV to Operating Cash Flow-12.14
Balance Sheet
Sarepta Therapeutics has $788.49M in cash and marketable securities with $1.05B in debt, giving a net cash position of -$257.36M billion.
Cash & Marketable Securities$788.49M
Total Debt$1.05B
Net Cash-$257.36M
Net Cash Per Share-$2.44
Tangible Book Value Per Share$10.61
Margins
Gross margin is 58.56%, with operating margin of -29.92%, and net profit margin of -32.45%.
Gross Margin58.56%
Operating Margin-29.92%
Pretax Margin-31.94%
Net Profit Margin-32.45%
EBITDA Margin-29.48%
EBIT Margin-31.50%
Analyst Forecast
The average price target for Sarepta Therapeutics is $22.63, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$22.63
Price Target Upside44.29% Upside
Analyst ConsensusHold
Analyst Count17
Revenue Growth Forecast-2.20%
EPS Growth Forecast77.51%